Esophageal StricturePhase 2NCT06840561
Local Triamcinolone Injection Combined With Fibrin Glue Spray in Preventing Esophageal Stricture After Big-range Endoscopic Submucosal Dissection for Esophageal Early Cancer
A Phase 2 study testing Local triamcinolone injection combined with fibrin glue spray in people with Esophageal Stricture and Endoscopic Submucosal Dissection, run by Sun Yat-Sen University Cancer Center at 1 site in China.
Trial summary
Endoscopic submucosal dissection (ESD) is the main treatment for esophageal early cancer. But post-ESD stricture has a serious impact on quality of life.When the lesion range reaches up to 3/4 circumferential mucosal defect or the longitudinal length over 5cm, the esophageal stricture rate will be over 70% or more… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Esophageal Stricture, Endoscopic Submucosal Dissection, Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
- What is being tested?
- Local triamcinolone injection combined with fibrin glue spray
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 24 Nov 2021to 10 Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- staged as cT1aN0M0 or cT1bN0M0 before surgery via magnifying endoscopy, endosonography, CT, or PET/CT;
- refuse conventional surgery and CRT and got ESD as first-line treatment;
- mucosal defect measured by a circular protractor and reached more than three-quarters of the circumference of the esophageal lumen including whole circumference after ESD surgery;
- meet the minimum follow-up period of three months;
- signed the consent before ESD;
- If extra treatment is needed after ESD, it is up to current guidelines.
Who cannot join
- excessive bleeding and perforation happened during the ESD procedure;
- excessive bleeding and perforation happened during TA injection;
- loss to follow-up or not meet three months follow-up periods;
- allergy to triamcinolone or fibrin glue;
- esophageal recurrence in situ during follow-up period
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Local Triamcinolone Injection Combined With Fibrin Glue Spray in Preventing Esophageal Stricture After Big-range Endoscopic Submucosal Dissection for Esophageal Early Cancer: a Prospective Study
Endoscopic submucosal dissection (ESD) is the main treatment for esophageal early cancer. But post-ESD stricture has a serious impact on quality of life.When the lesion range reaches up to 3/4 circumferential mucosal defect or the longitudinal length over 5cm, the esophageal stricture rate will be over 70% or more, and when the whole circumferential mucosal defect, the rate is up to 100%. Local triamcinolone (TA) injection has positive effect on post-ESD stricture.But there are no uniform standards and results of the TA usage. Investigators also found a disadvantage that TA injection was hard to be absorbed completely in the submucosal layer and spilled over easily, which may decrease the preventive effect. The investigators tried to make a better protocol that could adjust the time and frequency of triamcinolone injection to improve the medicine duration of stay and decrease the stricture rate. So, the aim of this study was to investigate the efficacy and safety of TA injection in a new way for preventing post-ESD stricture.
This is a single-center prospective intervention study, and single-arm trial too, which is carried out at Sun Yat-Sen University Cancer Center in Guangzhou, China. Participants recruited into the study must meet the standards as follows: (a). be staged as cT1aN0M0 or cT1bN0M0 before surgery via magnifying endoscopy, endosonography, CT, or PET/CT; (b). refuse conventional surgery and CRT and get ESD as first-line treatment; (c). mucosal defect measured by a circular protractor and reached more than three-quarters of the circumference of the esophageal lumen including whole circumference after ESD surgery; (d). sign the consent before ESD;(e). meet the minimum follow-up period of three months. In the protocol, TA injection combined with fibrin glue was used twice, immediately (D0) and 7days(D7) after ESD to increase TA's residual time and effect in the study group. Meanwhile, the stickiness of fibrin glue can protect the wound for preventing perforation or bleeding. The dosage of TA and fibrin glue were 100mg and 5-10ml in every session separately. The first target of this study was the frequency of stricture lasting at least three months follow-ups. And the second targets were the number of endoscopic bougie dilation or balloon dilation (EBD), stricture classification, stooler score and complications in the study group.
The expectational results are as follows: the first is that TA injection combined with firin glue spray can greatly decrease the esophgeal stricture rate after long-range ESD; the second is that TA injection combined with firin glue spray can also decrease the frequency of endoscopic bougie dilation or balloon dilation (EBD), complications, and the degree of stricture classification and stooler score compared with historical data. This study will show that TA injection combined with fibrin glue spray is a safe and effective treatment in preventing post-ESD stricture of esophageal early cancer.
Read the detailed description
Background Post-ESD stricture is becoming a more valued problem in multidisciplinary collaboration protocol.Most research about TA injection is single-center small sample retrospective research. It has a big difference in 3/4 circumferential mucosal defect or more. Hanaoka et al showed that TA injection could decrease the stricture rate to 10% in 3/4 circumferential mucosal defect or more. The control group without any preventive treatment had a 66% stricture rate.The scar healing lives through three stages after esophageal ESD, as follows: the first one is that submucosa or muscularis are exposed to food residuals, acid, bile reflux, and bacteria or fungus reproduction; the second is immune system is activated, mainly including granulation tissue hyperplasia, intraepithelial inflammatory cell infiltrating and neovascularization; the last is scar tissue formationThis phase mainly happens between the third day and the seventh after ESD. So, when is the appropriate time to intervene in suppressing scar formation? Methods ESD procedure Before ESD surgery, all participants signed written consent. Participants were under tracheal intubation anesthesia during ESD procedure. ESD was completed by three senior professors to decrease technology-related complications. During the resection, the investigators used Q260J endoscope (Olympus,Japan)with a water-jet system (Olympus,Japan) and transparent hood (Olympus,Japan). The other devices were as follows, 650-L needle-knife (Olympus,Japan), IT knife (Olympus,Japan), coagulation forceps (FD-410LR, Olympus,Japan), Submucosal injection needle (22Gauge,Olympus,Japan), and endocut machine (EREB,Germany). Standard operation procedures are as follows: (1). After delineating the tumor by 1.5% iodine staining, the investigator used a needle-knife to mark the boundary outside 0.5-1cm of tumor margin;(2). Then the operator blended the submucosal injection with mannitol, sodium hyaluronate, and methylene blue; (3). Needle-knife was used to dissect the elevated submucosa, and the procedure began from the anal side first, then came back oral side and dissected the whole lesion finally;(4) During the dissection, minor bleeding was stopped using needle-knife. But when middle or massive bleeding happened, the operator used coagulation forceps to coagulate the big vessels;(5) The specimen was stained again with iodine to ensure the lesion boundary and sent to the pathology room;(6) A pathology report must contain the size, differentiated grade, depth of invasion,margin and state of lymphatic vessel infiltration.
Locoregional triamcinolone injection and fibrin glue spray TA injection and fibrin glue spray were used in two sessions to prevent esophageal stricture, after ESD immediately(D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity was diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points(0.5ml/point) depending on the defective area. But TA injection must avoid muscular injury place. The operator checked the wound to make sure there was no bleeding or perforation after the TA injection, then sprayed 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage was depending on the wound area. The key point was that the glue could cover all the injection wound. Seven days later, the second TA injection and fibrin glue spray were carried out again. Before injection, the operator would check the wound carefully to exclude delayed perforation. A full dose of triamcinolone (100mg/25points) is strictly injected to minimize drug leakage in the process. If excessive leakage happened in the procedure due to underdosage, residual triamcinolone in ampul was used for isodose rescue. After injection, 5ml fibrin glue spray was used to cover the injection points. Because of high price, if the wound healed well, and participants disagreed to use, fibrin glue may not be used in D7.
Follow up and target The Stooler score classification was used to measure the dysphagia level internationally, as follows: 0: no dysphagia symptom, normal diet; I: dysphagia happens sometimes and can swallow soft solid food; II: participant can have a semi-liquid diet, for example porridge, and noodles; III: only a liquid diet such as rice-water/ milk/soup; IV: participant can have nothing even water or saliva.
Esophageal stricture was defined as couldn't get through by Q260 gastroscope (Olympus, Japan, diameter 9.2mm). If the Q260 gastroscope couldn't be used at the review date, another size scope like HQ290 or H290(Olympus, Japan) would be used with the exact diameter marked. When the normal scope couldn't pass, a transnaso-gastroscope (GIF-XP290N, Olympus, Japan, diameter 5.8mm) for children was chosen to check the scar healing condition. So depending on the diameter(D), stricture was classified as follows: Class 0: D≥10mm;Class I:6≤ D <10mm;Class II:D≤5mm.
For the whole circumferential mucosal resection, the first gastroendoscopy check was one month approximately after ESD. If stricture with Class 0, participants came back two months later for the next follow-up. But if participants had dysphagia of stooler II or more, stricture was reassessed by gastroendoscopy to make sure whether dilation needed. For the sub-circumferential mucosal resection, the first follow-up check was evaluated by stooler score classification. If the participant didn't have dysphagia symptoms and had a solid diet (stooler score :0-I), one came back three months later. But if the participants had dysphagia symptoms as score II or more, one needed to come back for stricture assessment to make sure whether dilation is needed by gastroendoscopy examination. Bougie dilation or balloon dilation was the first choice. Investigators recorded the total dilation times. All the participants needed a follow time of no less than three months and endoscopy reexaminations once at least. If the endoscopy was rejected, the Barium Esophagogram (BE) was replaced, and diameter was marked.
Treatment principles Participants who were diagnosed as cT1aN0M0 or cT1bN0M0 before surgery and showed pathological results as pT1bN0M0 with Lymphatic Vessel Infiltration (LVI) or positive margin were defined as non-curative resection (NCR). To prevent the risk of recurrence or metastasis, surgery or chemoradiotherapy (CRT) became good choices, especially CRT for the bad physical condition participants.
- Conditions
- Esophageal Stricture, Endoscopic Submucosal Dissection, Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
- Being tested
- Local triamcinolone injection combined with fibrin glue spray
- Keywords
- Local triamcinolone injection, fibrin glue spray, endoscopic submucosal dissection, esophageal stricture
- Medical subject headings
- Esophageal Stenosis, Esophageal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Local triamcinolone injection combined with fibrin glue sprayDrug
TA injection and fibrin glue spray are used in two sessions after ESD immediately (D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity is diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points (0.5ml/point) depending on the defective area. But TA injection should avoid muscular injury place. We check the wound to make sure there is no bleeding or perforation after the TA injection, then spray 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage is depending on the wound area. The key point is that the glue could cover all the injection wound. Seven days later, the protocol is carried out again.
| Study group | Role | What they receive |
|---|---|---|
| the study group | Experimental | Not described Receives: Drug: Local triamcinolone injection combined with fibrin glue spray |
What is being measured
The primary outcome is the main question the study is designed to answer.
The frequency of post-ESD stricture
After three months follow-ups, the stricture rate will be calculated in the study group with Local triamcinolone injection combined with fibrin glue spray. Esophageal stricture is defined as couldn't get through by Q260 gastroscope (Olympus, Japan, diameter 9.2mm).
Measured: From ESD surgery to the end of follow-up at least three months
Secondary outcomes (1)
The number of endoscopic bougie dilation or balloon dilation (EBD) and degree of stricture classification, and stooler score in the study group
After the three months follow-up, endoscopy is carried out to the diameter of esophagus. According to the diameter and feeding type, the stricture classification and stooler score are confirmed. If the patient begin to have endoscopic bougie dilation or balloon dilation (EBD), the numbers of EBD are recorded before the follow-up deadline.
Measured: The time frame of degree of stricture classification and stooler score is three months follow-up. The time frame of EBD is from the date of stricture confirmed untile the date of study ended.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2025
- Study start24 Nov 2021
- Primary completion10 Dec 2024
- Study completion10 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal StrictureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sun Yat-Sen University Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yang Qing, Sun Yat-sen University
- Investigators
- Qing Yang, MM, Principal investigator, Sun Yat-Sen University Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06840561
- Sponsor's protocol ID
- G2021-075-01
- Other IDs
- A2022440
- Status last verified
- Jan 2025
- First submitted
- 16 Feb 2025
- Last updated
- 21 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Local Triamcinolone Injection Combined With Fibrin Glue Spray in Preventing Esophageal Stricture After Big-range Endoscopic Submucosal Dissection for Esophageal Early Cancer: a Prospective Study
- ClinicalTrials.gov ID
- NCT06840561
- Acronym / sponsor ID
- G2021-075-01
- Conditions
- Esophageal Stricture, Endoscopic Submucosal Dissection, Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
- Keywords
- Local triamcinolone injection, fibrin glue spray, endoscopic submucosal dissection, esophageal stricture
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Sun Yat-Sen University Cancer CenterUniversity, hospital or other
- Study start
- 24 Nov 2021 (actual)
- Primary completion
- 10 Dec 2024 (actual)
- Study completion
- 10 Dec 2024 (actual)
- First posted
- 21 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endoscopic submucosal dissection (ESD) is the main treatment for esophageal early cancer. But post-ESD stricture has a serious impact on quality of life.When the lesion range reaches up to 3/4 circumferential mucosal defect or the longitudinal length over 5cm, the esophageal stricture rate will be over 70% or more, and when the whole circumferential mucosal defect, the rate is up to 100%. Local triamcinolone (TA) injection has positive effect on post-ESD stricture.But there are no uniform standards and results of the TA usage. Investigators also found a disadvantage that TA injection was hard to be absorbed completely in the submucosal layer and spilled over easily, which may decrease the preventive effect. The investigators tried to make a better protocol that could adjust the time and frequency of triamcinolone injection to improve the medicine duration of stay and decrease the stricture rate. So, the aim of this study was to investigate the efficacy and safety of TA injection in a new way for preventing post-ESD stricture.
This is a single-center prospective intervention study, and single-arm trial too, which is carried out at Sun Yat-Sen University Cancer Center in Guangzhou, China. Participants recruited into the study must meet the standards as follows: (a). be staged as cT1aN0M0 or cT1bN0M0 before surgery via magnifying endoscopy, endosonography, CT, or PET/CT; (b). refuse conventional surgery and CRT and get ESD as first-line treatment; (c). mucosal defect measured by a circular protractor and reached more than three-quarters of the circumference of the esophageal lumen including whole circumference after ESD surgery; (d). sign the consent before ESD;(e). meet the minimum follow-up period of three months. In the protocol, TA injection combined with fibrin glue was used twice, immediately (D0) and 7days(D7) after ESD to increase TA's residual time and effect in the study group. Meanwhile, the stickiness of fibrin glue can protect the wound for preventing perforation or bleeding. The dosage of TA and fibrin glue were 100mg and 5-10ml in every session separately. The first target of this study was the frequency of stricture lasting at least three months follow-ups. And the second targets were the number of endoscopic bougie dilation or balloon dilation (EBD), stricture classification, stooler score and complications in the study group.
The expectational results are as follows: the first is that TA injection combined with firin glue spray can greatly decrease the esophgeal stricture rate after long-range ESD; the second is that TA injection combined with firin glue spray can also decrease the frequency of endoscopic bougie dilation or balloon dilation (EBD), complications, and the degree of stricture classification and stooler score compared with historical data. This study will show that TA injection combined with fibrin glue spray is a safe and effective treatment in preventing post-ESD stricture of esophageal early cancer.
Detailed description
Background Post-ESD stricture is becoming a more valued problem in multidisciplinary collaboration protocol.Most research about TA injection is single-center small sample retrospective research. It has a big difference in 3/4 circumferential mucosal defect or more. Hanaoka et al showed that TA injection could decrease the stricture rate to 10% in 3/4 circumferential mucosal defect or more. The control group without any preventive treatment had a 66% stricture rate.The scar healing lives through three stages after esophageal ESD, as follows: the first one is that submucosa or muscularis are exposed to food residuals, acid, bile reflux, and bacteria or fungus reproduction; the second is immune system is activated, mainly including granulation tissue hyperplasia, intraepithelial inflammatory cell infiltrating and neovascularization; the last is scar tissue formationThis phase mainly happens between the third day and the seventh after ESD. So, when is the appropriate time to intervene in suppressing scar formation? Methods ESD procedure Before ESD surgery, all participants signed written consent. Participants were under tracheal intubation anesthesia during ESD procedure. ESD was completed by three senior professors to decrease technology-related complications. During the resection, the investigators used Q260J endoscope (Olympus,Japan)with a water-jet system (Olympus,Japan) and transparent hood (Olympus,Japan). The other devices were as follows, 650-L needle-knife (Olympus,Japan), IT knife (Olympus,Japan), coagulation forceps (FD-410LR, Olympus,Japan), Submucosal injection needle (22Gauge,Olympus,Japan), and endocut machine (EREB,Germany). Standard operation procedures are as follows: (1). After delineating the tumor by 1.5% iodine staining, the investigator used a needle-knife to mark the boundary outside 0.5-1cm of tumor margin;(2). Then the operator blended the submucosal injection with mannitol, sodium hyaluronate, and methylene blue; (3). Needle-knife was used to dissect the elevated submucosa, and the procedure began from the anal side first, then came back oral side and dissected the whole lesion finally;(4) During the dissection, minor bleeding was stopped using needle-knife. But when middle or massive bleeding happened, the operator used coagulation forceps to coagulate the big vessels;(5) The specimen was stained again with iodine to ensure the lesion boundary and sent to the pathology room;(6) A pathology report must contain the size, differentiated grade, depth of invasion,margin and state of lymphatic vessel infiltration.
Locoregional triamcinolone injection and fibrin glue spray TA injection and fibrin glue spray were used in two sessions to prevent esophageal stricture, after ESD immediately(D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity was diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points(0.5ml/point) depending on the defective area. But TA injection must avoid muscular injury place. The operator checked the wound to make sure there was no bleeding or perforation after the TA injection, then sprayed 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage was depending on the wound area. The key point was that the glue could cover all the injection wound. Seven days later, the second TA injection and fibrin glue spray were carried out again. Before injection, the operator would check the wound carefully to exclude delayed perforation. A full dose of triamcinolone (100mg/25points) is strictly injected to minimize drug leakage in the process. If excessive leakage happened in the procedure due to underdosage, residual triamcinolone in ampul was used for isodose rescue. After injection, 5ml fibrin glue spray was used to cover the injection points. Because of high price, if the wound healed well, and participants disagreed to use, fibrin glue may not be used in D7.
Follow up and target The Stooler score classification was used to measure the dysphagia level internationally, as follows: 0: no dysphagia symptom, normal diet; I: dysphagia happens sometimes and can swallow soft solid food; II: participant can have a semi-liquid diet, for example porridge, and noodles; III: only a liquid diet such as rice-water/ milk/soup; IV: participant can have nothing even water or saliva.
Esophageal stricture was defined as couldn't get through by Q260 gastroscope (Olympus, Japan, diameter 9.2mm). If the Q260 gastroscope couldn't be used at the review date, another size scope like HQ290 or H290(Olympus, Japan) would be used with the exact diameter marked. When the normal scope couldn't pass, a transnaso-gastroscope (GIF-XP290N, Olympus, Japan, diameter 5.8mm) for children was chosen to check the scar healing condition. So depending on the diameter(D), stricture was classified as follows: Class 0: D≥10mm;Class I:6≤ D <10mm;Class II:D≤5mm.
For the whole circumferential mucosal resection, the first gastroendoscopy check was one month approximately after ESD. If stricture with Class 0, participants came back two months later for the next follow-up. But if participants had dysphagia of stooler II or more, stricture was reassessed by gastroendoscopy to make sure whether dilation needed. For the sub-circumferential mucosal resection, the first follow-up check was evaluated by stooler score classification. If the participant didn't have dysphagia symptoms and had a solid diet (stooler score :0-I), one came back three months later. But if the participants had dysphagia symptoms as score II or more, one needed to come back for stricture assessment to make sure whether dilation is needed by gastroendoscopy examination. Bougie dilation or balloon dilation was the first choice. Investigators recorded the total dilation times. All the participants needed a follow time of no less than three months and endoscopy reexaminations once at least. If the endoscopy was rejected, the Barium Esophagogram (BE) was replaced, and diameter was marked.
Treatment principles Participants who were diagnosed as cT1aN0M0 or cT1bN0M0 before surgery and showed pathological results as pT1bN0M0 with Lymphatic Vessel Infiltration (LVI) or positive margin were defined as non-curative resection (NCR). To prevent the risk of recurrence or metastasis, surgery or chemoradiotherapy (CRT) became good choices, especially CRT for the bad physical condition participants.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| the study group | Experimental | Drug: Local triamcinolone injection combined with fibrin glue spray |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- staged as cT1aN0M0 or cT1bN0M0 before surgery via magnifying endoscopy, endosonography, CT, or PET/CT;
- refuse conventional surgery and CRT and got ESD as first-line treatment;
- mucosal defect measured by a circular protractor and reached more than three-quarters of the circumference of the esophageal lumen including whole circumference after ESD surgery;
- meet the minimum follow-up period of three months;
- signed the consent before ESD;
Key exclusion criteria (5 listed)
- excessive bleeding and perforation happened during the ESD procedure;
- excessive bleeding and perforation happened during TA injection;
- loss to follow-up or not meet three months follow-up periods;
- allergy to triamcinolone or fibrin glue;
- esophageal recurrence in situ during follow-up period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Local triamcinolone injection combined with fibrin glue sprayTA injection and fibrin glue spray are used in two sessions after ESD immediately (D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity is diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points (0.5ml/point) depending on the defective area. But TA injection should avoid muscular injury place. We check the wound to make sure there is no bleeding or perforation after the TA injection, then spray 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage is depending on the wound area. The key point is that the glue could cover all the injection wound. Seven days later, the protocol is carried out again. | Drug | the study group |
Primary outcome
The frequency of post-ESD stricture
Time frame: From ESD surgery to the end of follow-up at least three months
After three months follow-ups, the stricture rate will be calculated in the study group with Local triamcinolone injection combined with fibrin glue spray. Esophageal stricture is defined as couldn't get through by Q260 gastroscope (Olympus, Japan, diameter 9.2mm).
1 secondary outcome
The number of endoscopic bougie dilation or balloon dilation (EBD) and degree of stricture classification, and stooler score in the study group
Time frame: The time frame of degree of stricture classification and stooler score is three months follow-up. The time frame of EBD is from the date of stricture confirmed untile the date of study ended.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2025.
- Individual participant dataSharing planned: Yes
Related trials for Esophageal Stricture
Enrolling by invitation
Adipose-derived Stem Cells in Treatment of Esophageal Strictures
Esophageal Stenosis Acquired
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Prospective Evaluation of AI-ECG for SHD Detection
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis)
RecruitingObservational study
Abbott Cephea Mitral Valve Disease Registry
Mitral Regurgitation, Mitral Stenosis
Recruiting
Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions
Dysphagia, Esophageal Stricture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Qing Yang, MM principal investigator
Sun Yat-Sen University Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Local triamcinolone injection combined with fibrin glue spray in people with Esophageal Stricture and Endoscopic Submucosal Dissection, run by Sun Yat-Sen University Cancer Center at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The frequency of post-ESD stricture (time frame: From ESD surgery to the end of follow-up at least three months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2025.